Biohaven Reports Q2 2026 Financial Results, Initiates Phase 3 Clinical Trials
Biohavens new extracellular protein degraders showed robust clinical safety and efficacy, paving the way for multiple registrational programs. Clinical data for the epilepsy drug opakalim remains on track.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day